Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Toni K. Choueiri, MD, on Selecting Treatment for Advanced Kidney Cancer: Findings From the CLEAR Trial

Posted: Thursday, March 25, 2021

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the clinical implications of new findings from the CLEAR trial on the use of lenvatinib plus pembrolizumab or everolimus vs sunitinib to treat patients with advanced renal cell carcinoma.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.